TG Therapeutics, Inc. (FRA:NKB2)

TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of EUR 3.98 billion. The enterprise value is 4.09 billion.

Market Cap	3.98B
Enterprise Value	4.09B

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.20M
Shares Outstanding	n/a
Shares Change (YoY)	+11.64%
Shares Change (QoQ)	-0.96%
Owned by Insiders (%)	3.93%
Owned by Institutions (%)	71.62%
Float	140.39M

Valuation Ratios

The trailing PE ratio is 10.44 and the forward PE ratio is 22.63.

PE Ratio	10.44
Forward PE	22.63
PS Ratio	8.79
PB Ratio	7.70
P/TBV Ratio	7.70
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 45.32, with an EV/FCF ratio of -68.29.

EV / Earnings	10.72
EV / Sales	8.94
EV / EBITDA	45.32
EV / EBIT	46.25
EV / FCF	-68.29

Financial Position

The company has a current ratio of 3.82, with a Debt / Equity ratio of 0.42.

Current Ratio	3.82
Quick Ratio	2.53
Debt / Equity	0.42
Debt / EBITDA	2.43
Debt / FCF	-3.62
Interest Coverage	3.77

Financial Efficiency

Return on equity (ROE) is 111.96% and return on invested capital (ROIC) is 9.82%.

Return on Equity (ROE)	111.96%
Return on Assets (ROA)	7.97%
Return on Invested Capital (ROIC)	9.82%
Return on Capital Employed (ROCE)	11.84%
Revenue Per Employee	1.21M
Profits Per Employee	1.02M
Employee Count	338
Asset Turnover	0.66
Inventory Turnover	0.67

Taxes

Income Tax	-306.59M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -11.55% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-11.55%
50-Day Moving Average	28.90
200-Day Moving Average	30.32
Relative Strength Index (RSI)	52.86
Average Volume (20 Days)	70

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	12.83

Income Statement

In the last 12 months, TG Therapeutics had revenue of EUR 453.34 million and earned 381.38 million in profits. Earnings per share was 2.37.

Revenue	453.34M
Gross Profit	386.88M
Operating Income	87.60M
Pretax Income	74.79M
Net Income	381.38M
EBITDA	87.64M
EBIT	87.60M
Earnings Per Share (EPS)	2.37

Balance Sheet

The company has 112.15 million in cash and 216.94 million in debt, giving a net cash position of -104.80 million.

Cash & Cash Equivalents	112.15M
Total Debt	216.94M
Net Cash	-104.80M
Net Cash Per Share	n/a
Equity (Book Value)	517.53M
Book Value Per Share	3.63
Working Capital	377.53M

Cash Flow

In the last 12 months, operating cash flow was -59.72 million and capital expenditures -143,186, giving a free cash flow of -59.87 million.

Operating Cash Flow	-59.72M
Capital Expenditures	-143,186
Free Cash Flow	-59.87M
FCF Per Share	n/a

Margins

Gross margin is 85.34%, with operating and profit margins of 19.32% and 84.13%.

Gross Margin	85.34%
Operating Margin	19.32%
Pretax Margin	16.50%
Profit Margin	84.13%
EBITDA Margin	19.33%
EBIT Margin	19.32%
FCF Margin	n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.64%
Shareholder Yield	-11.64%
Earnings Yield	9.58%
FCF Yield	-1.50%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TG Therapeutics has an Altman Z-Score of 6.79 and a Piotroski F-Score of 3.

Altman Z-Score	6.79
Piotroski F-Score	3